All News

Previously treated patients with advanced renal cell carcinoma saw a higher overall survival rate with Cabometyx when compared to those on Afinitor, according to a phase 3 study.

A recent study explored six cancer-related dilemmas: understanding diagnosis; treatment planning; communication with the care team; finance and insurance issues; symptoms, side effects and quality of life; and survivorship.

When a loved one is diagnosed with cancer, the term "normal" has to be redefined.

Coming face-to-face with a cancer diagnosis not only shakes the very ground beneath one’s feet, it sends tremors throughout the mental landscape that constitute one’s worldview.

Avastin plus a novel antiangiogenic gene therapy resulted in significantly better overall survival for patients with recurrent glioblastoma multiforme.

When Darzalex was added to Velcade and dexamethasone, patients with relapsed multiple myeloma had a reduced risk of disease progression or death, according to a recent phase 3 trial.

The combination of Opdivo and Yervoy is showing promise as a treatment for PD-L1-Positive Non-Small Cell Lung Cancer, according to the results of a recent study.

Opdivo showed a higher-than-average OS rate and presented no grade 3/4 adverse events in patients with recurrent glioblastoma multiforme, according to a recent study.

When life feels really big, it's natural to see only the worst case scenario. It's natural to see catastrophe looming. Whether or not a catastrophe is on the horizon, it is out of our control. So perhaps it is more fruitful to keep ourselves in the here and now, in order to live our best life possible.

This cancer survivor still struggles with scanxiety and the cancer waiting and watching game.

Patients treated with Xtandi had higher rates of fatigue and pain than those who were treated with Zytiga and prednisone, resulting in a higher likelihood that they will reduce their treatment dose.

Tumor Treating Fields were determined safe to use as a fronline therapy for unresectable pancreatic cancer.

The experimental immunotherapy avelumab demonstrated durable responses and promising early survival data for patients with pretreated metastatic Merkel cell carcinoma.

Multiplex gene testing may not bring about unnecessary surgery or adverse psychological effects, according to findings from a recent study.

A population-based study revealed that less black women are tested or treated for BRCA mutations when compared with white and Hispanic women.

Organizations across America are dedicated to making sure patients with cancer look and feel beautiful.

The battle does not always end with the word.

Ed's weakened immune system plagues him for the last time.

According to results from a phase 3 study, Opdivo improved overall survival and objective response rates for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Phase 2 data presented at ASCO showed that Tafinlar plus Mekinist was a highly effective treatment regimen for patients with BRAF V600E-mutant NSCLC.

Binimetinib, an experimental targeted drug, reduced the risk of disease progression or death in patients with NRAS-mutant metastatic melanoma in a recent phase 3 study.

In a recent study, patients with lung cancer who used an online app to track their symptoms saw a higher overall survival rate than those who didn't.

If you really break it down, there are only two emotions that consume the world and all its living beings: love and fear.

Ed's weakened immune system continues to haunt him.

At the 2016 ASCO Annual Meeting, the vice president called for a commitment to team science, improved patient access to clinical trials, and announced a new cancer genomic and clinical data-sharing resource.

Aggressive end-of-life care is often harmful to patients and their families, yet is still so widely used.

In the longest follow-up of an anti-PD-1 immunotherapy in RCC, about one-third of the patients treated with single-agent Opdivo are still alive four and five years later.

Women are reducing their risk of recurrence by extending their adjuvant therapy with an aromatase inhibitor (AI) to 10 years after treatment for their early-stage HR-positive breast cancer.

Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.

Breast cancer can bring the surprise of lymphedema to the unsuspecting, uniformed patient.